share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股sec公告 ·  05/06 09:33
Moomoo AI 已提取核心信息
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, has announced that it has exceeded the Nasdaq's minimum stockholders' equity requirement of $2.5 million, as per Nasdaq Listing Rule 5550(b)(1). The company reported on May 6, 2024, that its stockholders' equity is significantly above the threshold, indicating regained compliance with the equity rule. Allarity is now awaiting formal confirmation from Nasdaq regarding its compliance status. Concurrently, Allarity has decided to withdraw its Registration Statement on Form S-1, initially filed with the SEC on October 30, 2023. This move comes after a reassessment of the company's financial position and recent improvements in equity status. CEO Thomas Jensen expressed confidence in the company's regulatory alignment and its focus on advancing stenoparib, a therapy for advanced ovarian cancer, using its proprietary Drug Response Predictor (DRP®) companion diagnostic. The company plans to disclose the updated equity amount in its upcoming Form 10-Q, expected to be filed on May 14, 2024, which will provide detailed financial insights to stockholders.
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, has announced that it has exceeded the Nasdaq's minimum stockholders' equity requirement of $2.5 million, as per Nasdaq Listing Rule 5550(b)(1). The company reported on May 6, 2024, that its stockholders' equity is significantly above the threshold, indicating regained compliance with the equity rule. Allarity is now awaiting formal confirmation from Nasdaq regarding its compliance status. Concurrently, Allarity has decided to withdraw its Registration Statement on Form S-1, initially filed with the SEC on October 30, 2023. This move comes after a reassessment of the company's financial position and recent improvements in equity status. CEO Thomas Jensen expressed confidence in the company's regulatory alignment and its focus on advancing stenoparib, a therapy for advanced ovarian cancer, using its proprietary Drug Response Predictor (DRP®) companion diagnostic. The company plans to disclose the updated equity amount in its upcoming Form 10-Q, expected to be filed on May 14, 2024, which will provide detailed financial insights to stockholders.
临床阶段的生物制药公司Allarity Therapeutics, Inc.（纳斯达克股票代码：ALLR）宣布，根据纳斯达克上市规则5550（b）（1），它已超过纳斯达克规定的250万美元的最低股东权益要求。该公司于2024年5月6日报告称，其股东权益大大高于门槛，这表明已恢复遵守股权规则。Allarity目前正在等待纳斯达克对其合规状况的正式确认。同时，Alarity已决定撤回其最初于2023年10月30日向美国证券交易委员会提交的S-1表格注册声明。此举是在重新评估了公司的财务状况以及最近股权状况的改善之后采取的。首席执行官托马斯·詹森对公司的监管协调以及专注于使用其专有的药物反应预测器（DRP®）伴随诊断来推进晚期卵巢癌治疗的stenoparib表示了信心。该公司计划在即将发布的10-Q表格中披露最新的股本金额，该表格预计将于2024年5月14日提交，这将为股东提供详细的财务见解。
临床阶段的生物制药公司Allarity Therapeutics, Inc.（纳斯达克股票代码：ALLR）宣布，根据纳斯达克上市规则5550（b）（1），它已超过纳斯达克规定的250万美元的最低股东权益要求。该公司于2024年5月6日报告称，其股东权益大大高于门槛，这表明已恢复遵守股权规则。Allarity目前正在等待纳斯达克对其合规状况的正式确认。同时，Alarity已决定撤回其最初于2023年10月30日向美国证券交易委员会提交的S-1表格注册声明。此举是在重新评估了公司的财务状况以及最近股权状况的改善之后采取的。首席执行官托马斯·詹森对公司的监管协调以及专注于使用其专有的药物反应预测器（DRP®）伴随诊断来推进晚期卵巢癌治疗的stenoparib表示了信心。该公司计划在即将发布的10-Q表格中披露最新的股本金额，该表格预计将于2024年5月14日提交，这将为股东提供详细的财务见解。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息